Next Gen Immuno-Oncology Congress

June 21-22, 2018 | Philadelphia - USA
CONFERENCE SPEAKERS
Advisors
Stefan Glueck
Stefan Glueck
Senior Vice President, Global Medical Affairs,
Celgene


Stefan Glück, MD, PhD, is V.P. Global Medical Affairs, at Celgene Corporation since October 2014, and a hematologist and medical oncologist with focus on breast cancer. He has overseen oncology activities worldwide, as well as the Immuno-Oncology Program in solid tumors and hematology. Recently, his job requirements have shifted to include Early Assets. He previously served as a Sylvester Professor in the Department of Medicine at Miller School of Medicine, University of Miami, Florida until September 2014. From 2003–2008, he was the Clinical Director of the Braman Family Breast Cancer Institute, and from January 2009 - December 2010 Assistant Director of the Sylvester Comprehensive Cancer Center and Associate Chief, Division Hematology & Medical Oncology. He has authored or co-authored over 270 articles


Roy Baynes
Roy Baynes
Senior Vice President,
Merck


Roy Baynes is Senior Vice President Global Clinical Development and Chief Medical Officer at Merck Research Laboratories in Rahway, New Jersey. He was previously Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences and prior to that was Vice President Global Clinical Development and Therapeutic Area (TA) Head for Hematology / Oncology, at Amgen Inc. In the early years of his tenure at Amgen before becoming TA head of Hematology / Oncology in Clinical Development he was TA head for Hematology / Oncology in Global Medical Affairs. He graduated as a Medical Doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand, Johannesburg, South Africa. He has had a long and distinguished career in the haematology-oncology-and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching and administration. He is a member of many international societies, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has authored some 150 publications. He has been recurrently named among America’s top physicians. Before joining Amgen in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, an NCI designated Comprehensive Cancer Center, at Wayne State University, Detroit, Michigan, USA.


John Delaney
John Delaney
Executive Director, Research,
Amgen



Speakers
Eytan Barnea
Eytan Barnea
Founder and Chief Scientist,
BioIncept LLC



Ellen Pure
Ellen Pure
Professor and Chair, Department of Biomedical Sciences,
University of Pennsylvania



Terry Fisher
Terry Fisher
Director, Translational Science and Bioanalytical,
Vaccinex



Judi Wardwell-Swanson
Judi Wardwell-Swanson
Senior Application Scientist,
Insphero



Pirouz Daftarian
Pirouz Daftarian
Application Manager, IO/Vaccines,
MBL International /JSR Micro, Life Sciences Inc.



Raj Chavali
Raj Chavali
Senior Director,
Caris Lifesciences



Joost Oppenheim
Joost Oppenheim
Head, Cellular Immunology,
NIH


Dr. Oppenheim is a Principal Investigator and Chief of the section of Cellular Immunity of the Cancer and Inflammation Program at the National Cancer Institute which focuses on the effects of inflammation and the immune response on cancer. Dr. Oppenheim obtained his M.D. degree from the Columbia College of Physicians and Surgeons, New York, trained as a clinical associate at the National Cancer Institute (NCI), Bethesda, Maryland, and was a postdoctoral fellow at the University of Birmingham, England, in immunology. He returned to the National Institute of Dental Research and subsequently headed the Section of Cellular Immunology. Dr. Oppenheim pioneered the development of cytokine, chemokine and alarmin fields of research. He is currently studying the role of alarmins that activate toll-like receptors, in inducing immunity to cancer. He has been engaged in translational studies aimed at utilizing alarmins as adjuvants in vaccines for use against infectious agents and tumors. He is also investigating means of blocking the immunosuppressive limb of immunity as exerted by T regulatory cells to augment antitumor immunity.


Christophe Queva
Christophe Queva
Chief Scientific Officer,
Oncorus



Ashok Shrivastava
Ashok Shrivastava
CEO,
Cure Pharmaceuticals



Mark Gardner
Mark Gardner
CEO,
OmniSeq



Patrick Hanley
Patrick Hanley
Director, GMP for Immunotherapy, Assistant Professor,
Children’s National Medical Centre



Frank Walsh
Frank Walsh
CEO,
Ossianix Inc.



Mithun Khattar
Mithun Khattar
Immuno-Oncology Lead,
Takeda Oncology



Lata Jayaraman
Lata Jayaraman
Head, Tumor Immunotherapy,
Seres Therapeutics



Gregory Alberts
Gregory Alberts
Global Subject Matter Expert,
Lonza Pharma Bioscience Solutions



Mark Paris
Mark Paris
Associate Director, Translational Applications,
Mitra Biotech



Holly Koblish
Holly Koblish
Director, Pharmacology,
ncyte



Papia Chakraborty
Papia Chakraborty
Senior Scientist, Head, Immuno-Oncology,
Medgenome



Pramod Srivastava
Pramod Srivastava
Director of the Carole and Ray Neag Comprehensive Cancer Cente,
University of Connecticut



Roy Baynes
Roy Baynes
Senior Vice President,
Merck


Roy Baynes is Senior Vice President Global Clinical Development and Chief Medical Officer at Merck Research Laboratories in Rahway, New Jersey. He was previously Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences and prior to that was Vice President Global Clinical Development and Therapeutic Area (TA) Head for Hematology / Oncology, at Amgen Inc. In the early years of his tenure at Amgen before becoming TA head of Hematology / Oncology in Clinical Development he was TA head for Hematology / Oncology in Global Medical Affairs. He graduated as a Medical Doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand, Johannesburg, South Africa. He has had a long and distinguished career in the haematology-oncology-and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching and administration. He is a member of many international societies, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has authored some 150 publications. He has been recurrently named among America’s top physicians. Before joining Amgen in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, an NCI designated Comprehensive Cancer Center, at Wayne State University, Detroit, Michigan, USA.


John Delaney
John Delaney
Executive Director, Research,
Amgen



Ildiko Csiki
Ildiko Csiki
Vice President, Clinical Development Immuno- Oncology,
Inovio



Ezio Bonvini
Ezio Bonvini
Senior Vice President, CSO,
MacroGenics



Stephen Schoenberger
Stephen Schoenberger
Professor of Immunology,
La Jolla Institute for Allergy and Immunology



Andrew Allen
Andrew Allen
CEO,
Gritstone Oncology



Wei Zhou
Wei Zhou
Senior Research Scientist,
The Jackson Laboratory



Rakesh Dixit
Rakesh Dixit
CEO,
Bionavigen


Rakesh Dixit is a President & CEO, BIONAVIGEN, LLC, a biopharmaceutical virtual drug development company specializing in advising and consulting for all aspects of drug development, including discovery, preclinical development, CMC, translational sciences, clinical development and regulatory filing. Accomplished executive, inventor, and scientist with over 30 years of success with top biotechnology and pharmaceutical companies, including Merck, Johnson & Johnson, Medimmune, AstraZeneca.


Stefan Glueck
Stefan Glueck
Senior Vice President, Global Medical Affairs,
Celgene


Stefan Glück, MD, PhD, is V.P. Global Medical Affairs, at Celgene Corporation since October 2014, and a hematologist and medical oncologist with focus on breast cancer. He has overseen oncology activities worldwide, as well as the Immuno-Oncology Program in solid tumors and hematology. Recently, his job requirements have shifted to include Early Assets. He previously served as a Sylvester Professor in the Department of Medicine at Miller School of Medicine, University of Miami, Florida until September 2014. From 2003–2008, he was the Clinical Director of the Braman Family Breast Cancer Institute, and from January 2009 - December 2010 Assistant Director of the Sylvester Comprehensive Cancer Center and Associate Chief, Division Hematology & Medical Oncology. He has authored or co-authored over 270 articles


Daniel Powell
Daniel Powell
Associate Professor of Pathology and Laboratory Medicine,
University of Pennsylvania



Daniel Levey
Daniel Levey
Senior Director Vaccine Research,
Agenus



Wendy Clemens
Wendy Clemens
Vice President, Clinical Development,
Nektar Therapeutics



Natalie Russi
Natalie Russi
Scientific Project Manager,
Nebion


Natalie Russi works as Scientific Project Manager for NEBION AG, the premier provider of curated gene expression data and tools for innovative biopharmaceutical research.  As PhD-level scientist from ETH Zurich her expertise is in the field of transcriptomics. Natalie is passionate about oncology and wants to advance immuno-oncology research by supporting researchers to harness the great potential of public gene expression data.


Lisa McNeil
Lisa McNeil
Director, Translational Medicine,
Genocea



Wayne Godfrey
Wayne Godfrey
Senior Director, Clinical Development,
Kite Pharma



Liang Deng
Liang Deng
Associate Member, Attending Physician,
Memorial Sloan Kettering Cancer Centre



Christopher Bunker
Christopher Bunker
Vice President, Business Development,
ACD-Bio-Biotechne